Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annder.2020.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe verrucous erythema elevatum diutinum responding to a combined therapy with low-dose dapsone and prednisone.
Clin Exp Dermatol
January 2025
Dermatology department, Dupuytren 2 University Hospital, Limoges, France.
Comparison of topical dapsone + tretinoin and clindamycin + tretinoin combination in terms of effectiveness in the treatment of mild and moderate acne vulgaris: a retrospective analysis.
Arch Dermatol Res
January 2025
Department of Dermatology, Hitit University, Erol Olçok Training and Research Hospital, Çorum, Türkiye.
Treatment of facial reactive B-cell rich lymphoid proliferation with dapsone.
J Dermatol
January 2025
Department of Dermatology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
Reactive B-cell rich lymphoid proliferation (rB-LP), once called pseudolymphoma, is a benign lymphoproliferative disorder, which is histologically characterized by dense dermal infiltrate forming reactive germinal centers with tingible body macrophages. The disease frequently involves the face, scalp, and ear lobes. Treatment includes topical or intralesional steroids, surgical resection, ultraviolet therapy, laser treatment, and radiation therapy.
View Article and Find Full Text PDFRepurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders.
Biomolecules
November 2024
Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy.
Neutrophil-mediated inflammation is a key feature of immune-mediated chronic skin disorders, but the mechanistic understanding of neutrophil involvement in these conditions remains incomplete. Dapsone, colchicine, and tetracyclines are established drugs within the dermatologist's therapeutic armamentarium that are credited with potent anti-neutrophilic effects. Anti-neutrophilic drugs have established themselves as versatile agents in the treatment of a wide range of dermatological conditions.
View Article and Find Full Text PDFPrognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris.
Acta Derm Venereol
January 2025
Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel.
Pemphigus vulgaris is a chronic autoimmune blistering disease with significant morbidity. Rituximab, approved as its first-line treatment, effectively induces remission. However, few studies have analysed the prognostic factors for improved rituximab outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!